Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Pediatric Blood & Cancer|October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park, Judith G Villablanca, Wendy B London, et al.
Cancer Genetics|July 12, 2015
Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology GroupMarijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, et al.
Disease Models & Mechanisms|October 30, 2012
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastomaDamini Chand, Yasuo Yamazaki, Kristina Ruuth, et al.
Blood|April 16, 2017
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group reportMarijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, et al.
Plos Genetics|March 26, 2011
Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility LociLe B Nguyen, Sharon J Diskin, Mario Capasso, et al.
The New England Journal of Medicine|November 25, 2005
Chromosome 1p and 11q deletions and outcome in neuroblastomaEdward F Attiyeh, Wendy B London, Yael P Mossé, et al.
Nature Genetics|September 4, 2012
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastomaSharon J Diskin, Mario Capasso, Robert W Schnepp, et al.
Cancer Cell|October 21, 2015
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma TumorigenesisRobert W Schnepp, Priya Khurana, Edward F Attiyeh, et al.
Pediatric Blood & Cancer|September 24, 2015
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing programEdward F Attiyeh, John M Maris, Richard Lock, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2011
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaKristina A Cole, Jonathan Huggins, Michael Laquaglia, et al.
Pageof 4